Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 2
Submit an article Journal homepage
216
Views
6
CrossRef citations to date
0
Altmetric
Review

Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review

Phool Iqbala Department of Internal Medicine, Hamad Medical Corporation, (HMC), Doha, QatarView further author information
,
Ashraf Solimanb Pediatrics and Endocrinology Department of Pediatrics, Hamad Medical Center, Doha, Qatar;c Department of Pediatrics, University of Alexandria, Alexandria, EgyptView further author information
,
Vincenzo De Sanctisd Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, ItalyView further author information
&
Mohamed A. Yassine Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, QatarCorrespondence[email protected]
View further author information
Pages 211-217 | Received 25 Jul 2020, Accepted 11 Jan 2021, Published online: 21 Jan 2021

References

  • Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017 [Published 2017 Apr 24];8:469.
  • Granatowicz A, Piatek CI, Moschiano E, et al. An overview and update of chronic myeloid, leukemia for primary care physicians. Korean J Fam Med. 2015;36:197–202.
  • Thompson PA, Kantarjian H, Cortes JE. Diagnosis and treatment of chronic myeloid, leukemia (CML) in 2015. Mayo Clin Proc. 2015;90(10):1440–1454.
  • Shu C, Liao K, Chen Y, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep. 2019 [Published 2019 Aug 15];9(1):11901.
  • Senn L, Kovacsovics T, Tarr PE, et al. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med. 2009;169:312–316.
  • Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37–49.
  • Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine (Baltimore). 2017;96(28):e7482.
  • Cao L, Greenblatt DJ, Kwara A. Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug Metab Dispos. 2017;45:1035–1043.
  • Liu C-J, Hong Y-C, Teng CJ, et al. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan. Int J Cancer. 2015;136:1881–1887.
  • Climent N, Plana M. Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection. Front Pharmacol. 2019;10:1232.
  • Daniels JMA, Vonk-Noordegraaf A, Janssen JJ, et al. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2009;33:670–672.
  • Glaziou P, Sismanidis C, Floyd K, et al. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2014;5(2):a017798.
  • Khan FY, Dosa K, Fuad A, et al. W disseminated tuberculosis among adult patients admitted to hamad general hospital, Qatar: a five year hospital based study. Mycobact Dis. 2016;6:2.
  • Bhuian TM, Rahman MM, Hoque MN, et al. Peritoneal tuberculosis in a patient with chronic myeloid leukemia and diabetes mellitus: a diagnostic dilemma. Mymensingh Med J. 2011;20:614–619.
  • Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373–1377.
  • de Lima Corvino DF, Kosmin AR. Tuberculosis Screening. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Jun 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK448205/
  • Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 2020;69:1–11.
  • Sarkar S, Ganguly A, Sunwoo HH. Current overview of anti-tuberculosis drugs: metabolism and toxicities. Mycobact Dis. 2016;6:2.
  • Gülbay BE, Gürkan ÖU, Yıldız ÖA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100:1834–1842.
  • Ghadyalpatil K, Prabhash K, Menon H, et al. Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. J Clin Oncol. 2010;28(15 (suppl)):6594.
  • Bhatnagar V, Adelakun A, Kendall T, et al. Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Arch Iran Med. 2015;18:65–68.
  • Sorà F, De Matteis S, Di Mario A, et al. Antituberculosis therapy and imatinib for chronic myeloid leukemia. Clin Infect Dis. 2006;43:1223.
  • Agaimy A, Brueckl V, Schmidt D, et al. Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor. Case Rep Oncol. 2013;6:134–142.
  • Kim DJ, Jeong S, Kong SG, et al. First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Blood Res. 2019;54:151–153.
  • Floyd K, Glaziou P, Zumla A, et al. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6:299–314.
  • Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol. 2004;53:102–106.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.